News Releases

View all Historical Press Releases

Month Year

Investor Alerts

Oct 25, 2016

Soligenix Receives European Medicines Agency Designation as Small and Medium Enterprise

Princeton, NJ – October 25, 2016 – Soligenix, Inc. (OTCQB: SNGXD) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Oct 18, 2016

Soligenix Announces Publication of its Phase 2 Clinical Trial Results of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

Positive Clinical Results Consistent with Preclinical Data

Princeton, NJ – October 18, 2016 – Soligenix, Inc. (OTCQB: SNGXD) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Oct 17, 2016

Soligenix to Receive $530,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

Princeton, NJ – October 17, 2016 – Soligenix, Inc. (OTCQB: SNGXD) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Oct 13, 2016

Soligenix Announces Poster Presentations from its Gastrointestinal Acute Radiation Syndrome Program at the 2016 Radiation Research Society Meeting

Princeton, NJ – October 13, 2016 – Soligenix, Inc. (OTCQB: SNGXD) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Oct 11, 2016

Soligenix Announces Poster Presentation of its Ricin Vaccine and Dusquetide Orphan Programs at the 2016 NORD Rare Diseases and Orphan Products Breakthrough Summit

Princeton, NJ – October 11, 2016 – Soligenix, Inc. (OTCQB: SNGXD) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa